M-002

N/A

Report date: 2024/02/05 14:01:58

Base Information

Drug NameM-002
Drug Alias NameM-002DM-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-MUC1Anti-Receptor tyrosine-protein kinase erbB-3
TargetsMucin-1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXadcera Biopharmaceutical (Suzhou) Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A